[FOXP3调节性T细胞预测乳腺癌患者新辅助化疗疗效的价值]
[Value of FOXP3 Tregs predicting the effectiveness of neoadjuvant chemotherapy in patients with breast cancer].
作者信息
Su Jing, Chen Hanghang, Li Mengquan, Dong Jiahan, Lin Zhiwei
机构信息
Department of Breast Surgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450000, China. Email:
Department of Breast Surgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450000, China.
出版信息
Zhonghua Yi Xue Za Zhi. 2015 Mar 3;95(8):595-7.
OBJECTIVE
To explore the predictive significance of FOXP3 Tregs in patients with breast cancer on neoadjuvant chemotherapy (NACT).
METHODS
A total of 78 newly diagnosed and untreated patients with invasive breast cancer were recruited for this retrospective study.FOXP3 Tregs were assessed by immunohistochemistry. The relationship between clinicopathological factors, FOXP3+ Tregs and pathological complete response (pCR) rate was analyzed.
RESULTS
Among 78 patients with TAC neoadjuvant chemotherapy, the pCR rate was 19.2%. The pCR rate of patients with high expressions of FOXP3+ Tregs was significantly lower than that of those with low expressions of FOXP3+ Tregs (9.5% vs 30.5%, P = 0.023). FOXP3+ Tregs expression in breast cancer and efficacy of NACT were negatively correlated.
CONCLUSION
FOXP3+ Tregs may serve as a predictor for assessing the efficacy of NACT.
目的
探讨乳腺癌患者中FOXP3调节性T细胞（Tregs）对新辅助化疗（NACT）的预测意义。
方法
本回顾性研究共纳入78例新诊断且未接受过治疗的浸润性乳腺癌患者。通过免疫组织化学评估FOXP3 Tregs。分析临床病理因素、FOXP3 + Tregs与病理完全缓解（pCR）率之间的关系。
结果
在78例接受TAC新辅助化疗的患者中，pCR率为19.2%。FOXP3 + Tregs高表达患者的pCR率显著低于FOXP3 + Tregs低表达患者（9.5%对30.5%，P = 0.023）。乳腺癌中FOXP3 + Tregs表达与NACT疗效呈负相关。
结论
FOXP3 + Tregs可作为评估NACT疗效的预测指标。
Zotero 插件